Indegene Limited has successfully concluded its postal ballot voting process on January 23, 2026, with shareholders overwhelmingly approving the appointment of Mr. Neeraj Bharadwaj as an Independent Director. The special resolution received strong support from the shareholder community, demonstrating confidence in the proposed board appointment.

Voting Results and Participation

The postal ballot process witnessed significant shareholder participation across different categories. The comprehensive voting results are detailed below:

The overall voting results show that 185805074 votes were cast in favour of the resolution, while 732944 votes were against, resulting in an approval rate of 99.61%.

Appointment Details and Process

The special resolution pertained to the appointment of Mr. Neeraj Bharadwaj (DIN: 01314963) as an Independent Director of the company. The postal ballot notice was issued on December 22, 2025, with the cut-off date for determining eligible shareholders set as December 12, 2025.

E-Voting Timeline and Compliance

The remote e-voting process remained open from Thursday, December 25, 2025, at 9:00 AM until Friday, January 23, 2026, at 5:00 PM. The voting was conducted in compliance with Sections 108 and 110 of the Companies Act, 2013, and Regulations 30 and 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Madhwesh K, Practicing Company Secretary (Membership No. A21477), served as the scrutinizer for the postal ballot process. The scrutinizer's report confirmed the validity of the voting process and results, with 1508177 votes from public institutions being classified as invalid.

Regulatory Compliance and Disclosure

The postal ballot results and scrutinizer's report have been made available at multiple locations for shareholder access:

• Company's registered office notice board
• Company website at www.indogene.com
• NSDL e-voting portal at www.evoting.nsdl.com

The company has fulfilled all regulatory requirements under the Companies Act, 2013, and SEBI regulations for conducting postal ballot through remote e-voting. The appointment of Mr. Neeraj Bharadwaj as Independent Director is now effective following the successful completion of the voting process.

Indegene Limited has announced the appointment of Ms. Jill Mary De Simone as Additional Director (Non-Executive Independent Director), marking a significant addition to the company's board leadership. The appointment was approved by the Board of Directors on January 22, 2026, based on the recommendation of the Nomination and Remuneration Committee.

Appointment Details

The key parameters of Ms. De Simone's appointment are outlined below:

Professional Background

Ms. De Simone brings extensive biopharmaceutical industry expertise to Indegene's board. She is an accomplished executive and board director with a distinguished career spanning leadership roles at major healthcare organizations. Her professional experience includes serving as former President of U.S. Oncology at Merck, where she managed full P&L responsibilities and launched transformative therapies across multiple therapeutic areas.

Her career encompasses leadership positions at prominent pharmaceutical companies including Merck, Teva, and Bristol Myers Squibb. During her tenure at these organizations, she successfully launched innovative therapies in oncology, HIV, women's health, and general medicine. Her expertise spans driving growth, innovation, and governance across global healthcare organizations.

Current Activities and Expertise

Currently, Ms. De Simone operates as an advisor to preclinical and early-stage companies, focusing on commercialization strategies and leadership transitions. She actively serves on boards of both public and private life sciences companies, bringing her strategic acumen to various organizations. Additionally, she chairs advisory boards that focus specifically on artificial intelligence applications in healthcare.

Her professional reputation centers on strategic leadership, authentic management style, and commitment to building purpose-driven organizational cultures. She demonstrates a particular passion for mentoring emerging leaders and shaping corporate governance practices within the healthcare sector.

Regulatory Compliance

Indegene has confirmed that Ms. De Simone meets all regulatory requirements for the director position. The company has affirmed that she is not debarred from holding the office of Director by virtue of any SEBI order or any other regulatory authority. This confirmation aligns with NSE circular NSE/CML/2018/24 and BSE circular LIST/COMP/14/2018-19, both dated June 20, 2018.

The appointment disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with regulatory requirements. The company has also confirmed that Ms. De Simone is not related to any existing Director of the Company, maintaining board independence standards.